Abstract
Dendritic cells (DCs) have the potential to elicit long-lasting anti-tumour immune responses. Most of the clinical trials of anti-cancer DC vaccines are based on monocyte-derived DCs (Mo-DCs). However, their outcomes have shown limited promise especially in multiple myeloma (MM) patients. Here, we investigated whether in vitro generated Mo-DCs from MM patients (MM-DCs) possess impaired functionality, thus contributing to the limited success of DC vaccines. We generated MM-DCs and compared them with DCs from healthy donors (HD-DCs). The yield of DCs in MM was 3.5 fold lower than in HD sets. However morphology, phenotype, antigen uptake and allo-T cell stimulation were comparable. Migration and secretion of IL12p70 and IFN-γ (in DC-T cell co-cultures) were significantly reduced in MM-DCs. Thus, MM-DCs were compromised in functionality. This impairment could be attributed to autocrine secretion of IL6 by MM-monocytes and activation of their P38 MAPK pathway. This indicates a need to look for alternative sources of DCs.
Highlights
Dendritic cells (DCs) play a pivotal role in the immune system by orchestrating T cell immune response
The mononuclear cell (MNC) population from HD and MM samples were analysed for expression of CD14 to test if there was a difference in the monocyte marker expression
DC cultures were established from adherent monocytes, after seeding equal number of Mono-nuclear cells (MNCs) as described earlier and the viable cells in the adherent fraction were taken
Summary
Dendritic cells (DCs) play a pivotal role in the immune system by orchestrating T cell immune response. They capture, process and present antigens to T cells. Multiple myeloma (MM) is a malignancy of plasma cells differentiated from B cells These cells continue to secrete immunoglobulin, which accumulates in the bone marrow and form lesions, hindering normal haematopoiesis. Treatments such as stem cell transplantation (SCT) and chemotherapy have increased the progression-free survival in multiple myeloma patients, they often undergo relapse. Autocrine secretion of IL6 and activation of the P38 MAPK pathway probably contribute to impaired migration of MM-DCs
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
